Mineralys Therapeutics Advances Lorundrostat Trial Progress
Company Announcements

Mineralys Therapeutics Advances Lorundrostat Trial Progress

An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available.

Mineralys Therapeutics has completed enrollment ahead of schedule for its Launch-HTN trial, part of a pivotal program evaluating lorundrostat for treating uncontrolled and resistant hypertension. With the trial set to finish earlier than expected, investors can anticipate topline results by mid-2025. The company aims to model real-world treatment scenarios and has received enthusiastic participation from both physicians and patients.

For detailed information about MLYS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMineralys Therapeutics Announces Q3 2024 Results and Updates
TheFlyMineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c)
Carrie WilliamsMineralys Therapeutics, Inc. (MLYS) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App